SynthesisMycoses2025
Therapeutic Outcomes in Patients With Trichophyton indotineae: A Systematic Review and Meta-Analysis of Individual Patient Data.
Synthesis in Mycoses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026.Antibiotics (Basel, Switzerland) · 2026Review
- Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions.American journal of clinical dermatology · 2026Review
- Comparison of gradient concentration strip and EUCAST methods for itraconazole and posaconazole MICs inAntimicrobial agents and chemotherapy · 2026Article
- Antimicrobial photodynamic therapy using sodium iron chlorophyllin against drug-resistant Cutibacterium acnes from patients with acne vulgaris.Scientific reports · 2026Article
- Global Emergence ofInfection and drug resistance · 2026Review
- [Trichophyton mentagrophytes ITS genotype VIII/Trichophyton indotineae in Germany-revisit after 5 years].Dermatologie (Heidelberg, Germany) · 2025Article
- Zoonotic and Anthropophilic Trichophyton mentagrophytes Complex Infection in Human: An Update and Narrative Review.Mycoses · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrichophyton indotineae has emerged as a significant global dermatophyte, associated with recalcitrant dermatophytosis and increasing antifungal resistance. MATERIALS AND
methodsThis study evaluates therapeutic outcomes in T. indotineae infections. We conducted a systematic review and meta-analysis of individual patient data adhering to PRISMA guidelines, including studies published before December 2023 from six electronic databases. Only studies with confirmed T. indotineae by rDNA sequencing and therapeutic outcome data were included.
resultsA total of 27 publications with 81 cases were included. T. indotineae infections affected both genders equally, with 25% having prior steroid use, which was significantly associated with non-improvement. Resistance to terbinafine was observed in 85.3% of cases. Oral itraconazole was significantly associated with a cure. The restricted median time to complete clinical cure was 11.50 weeks, with a recurrence rate of 19.7%.
conclusionsThe effective management of T. indotineae infections is essential, given the significant challenges posed by antifungal resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.